Cephalon Oncology is going further to maximize therapeutic potential and extend patient benefits worldwide. In addition to our drug discovery program, which is bringing transforming impetus to the management of hematological malignancies, we market several products internationally, two of which are commercialized in the United States:

TREANDA^® (bendamustine HCl)

TREANDA (bendamustine hydrocholride) for Injection is indicated for the treatment of patients with chronic lymphotic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established. For more information, please visit www.TREANDA.com.

See full prescribing information.

TRISENOX^® (arsenic trioxide)

TRISENOX is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. www.TRISENOX.com

See full prescribing information including BOXED WARNINGS.